INSTRUCTIONS TO AUTHORS

These instructions are abridged. Full instructions are published on the Journal’s website — http://wileyonlinelibrary.com/journal/pds. Click the link for ‘author guidelines.’ Authors are strongly advised to read the full instructions online prior to submitting.

1. AIMS AND SCOPE

The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology, defined broadly. Particular areas of interest include:

- design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
- comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
- methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
- assessments of harm versus benefit in drug therapy;
- patterns of drug utilization;
- relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
- evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.

2. MANUSCRIPT CATEGORIES

Pharmacoepidemiology and Drug Safety invites the following types of submission:

Original Reports — Original Reports are the Journal’s primary mode of scientific communication. Original Reports typically do not exceed 3,000 words of body text, excluding abstract, tables, figures and references.

Reviews — Reviews of ‘hot topics’ and controversies are welcome. Reviews should be of a critical nature, discussing all sides of a question in a balanced manner. Experts considering offering such a review should feel free to contact either of the Editors, as appropriate, in order to avoid unnecessary effort. All reviews will be peer-reviewed. Reviews typically should not exceed 3,000 words of body text (excluding abstract, figures, tables and references), and be limited to 150 references.

Brief Reports — Succinct data papers, and in highly unusual situations case reports (Pharmacoepidemiol Drug Saf 2007;16:473), will be considered for publication as Brief Reports. Brief Reports should not exceed 1,500 words, and be limited to 1 table, 1 figure and 15 references.

Commentaries — Commentaries cover a variety of topics of current interest in pharmacoepidemiology and pharmacovigilance, and the intersection between these disciplines and society. The Journal welcomes submissions and proposals. Commentaries are limited to 1,500 words and 15 references.

Letters to the Editor — Letters to the Editor are encouraged, and may be in response to issues arising from recently published articles, or short, free-standing pieces expressing an opinion. No abstract is required, and text should be formatted in one continuous section. Letters are limited to 1000 words.

Research Protocols — See online for specific criteria for submission.

Other — Reviews of books and other media may be submitted only at the invitation of the Editors. However, suggestions are welcome.

3. EDITORS AND PEER REVIEW

The Editor-in-Chief, Brian Strom (email: bstrom@upenn.edu), will apportion manuscripts to a Regional Editor based on location unless there are conflicts of interest between the paper’s authors and that regional office.

Papers from Americas will be handled by:
Vincent Lo Re—University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.
E-mail: vincentl@pennmedicine.upenn.edu

Papers from Europe will be handled by:
Hubert Leufkens—Utrecht University, Faculty of Science Utrecht Institute for Pharmaceutical Sciences (UIPS)
Division of Pharmacoepidemiology and Clinical Pharmacology
PO Box 80 082, 3508 TB Utrecht, The Netherlands
E-mail: H.G.M.Leufkens@uu.nl

Papers from Asia, Africa, the Middle East, and Oceania will be handled by:
Byung Joo Park—Seoul National University College of Medicine, Seoul, Korea
E-mail: bjpark@snu.ac.kr

A fast-track review and publication process is in place for particularly time-sensitive findings of urgent public health importance. The Editor-in-Chief should be contacted to begin this process.

4. SUBMISSION OF MANUSCRIPTS

All submissions should be made online at the Pharmacoepidemiology and Drug Safety Manuscript Central site—http://mc.manuscriptcentral.com/pds. New users should first create an account. Once a user is logged onto the site, submissions should be made via the ‘Author Centre’.

REVIEW

125 Run-in periods and clinical outcomes of antipsychotics in dementia: A meta-epidemiological study of placebo-controlled trials
T. A. Hulshof, S. U. Zuidema, C. C. Gispen-de Wied and H. J. Luijendijk

ORIGINAL REPORTS

134 Consumer understanding of the scope of FDA’s prescription drug regulatory oversight: A nationally representative survey

141 Exposure to guideline-recommended drugs after a first acute myocardial infarction in older adults: does deprivation matter?
A. E. Akator, C. Blais, P. Gamache, C. Lunghi and L. Guénette

150 Interrupted time series analysis on first cardiovascular disease hospitalization for adherence to lipid-lowering therapy
F. Hu, J. Warren and D. J. Exeter

161 Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
H. Tang, K. Yang, X. Li, Y. Song and J. Han

173 Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)
M. Tsuchiya, T. Obara, T. Sakai, K. Nomura, C. Takamura and N. Mano

182 The use of natural language processing to identify vaccine-related anaphylaxis at five health care systems in the vaccine safety Datalink

189 The role of prescription drugs in female overactive bladder syndrome—A population-wide cohort study
W. Umek, A. Gleiss, B. Bodner-Adler, B. Reichardt, C. Rinner and G. Heinze

199 Identifying sequential episodes of pharmacotherapy as a method for assessing treatment failure in comparative effectiveness research
G. Carney, M. Maclure, K. Bassett, S. Taylor and C. R. Dormuth

208 Comparison of medication adherence measures derived from linked administrative data and associations with mortality using restricted cubic splines in heart failure patients
X. Qin, J. Hung, M. W. Knuiman, T. G. Briffa, T.-H. K. Teng and F. M. Sanfilippo

BRIEF REPORT

219 Assessment of colistimethate sodium (COLOBREATHE) risk minimization measures implemented in the European Union: A cross-sectional study
S. Kaplan, O. Patino, C. Rainville and T. Madison

LETTERS TO THE EDITOR

224 Extreme polypharmacy: The need to mint a new term
J. E. Machado-Alba, M. E. Machado-Duque and A. Gaviria-Mendoza

226 Medical device postmarket clinical follow-up in Europe: Getting priorities right
A. Bratillon and S. Bewley

The cover image is based on the Original Report* Interrupted time series analysis on first cardiovascular disease hospitalization for adherence to lipid-lowering therapy by Feiyu Hu** et al., https://doi.org/10.1002/pds.4916.**